Biologics Treatmentsfor Allergies and Immune Conditions at The Allergy Group
At The Allergy Group, we offer cutting-edge biologic treatments to manage various allergic and immune system conditions. Biologics are targeted therapies derived from living cells that can provide significant relief for patients who have not responded well to conventional treatments. These therapies are administered through injections or oral medications and work by targeting specific parts of the immune system involved in allergic reactions and inflammation. Biologics target the immunologic pathology in chronic disease states and have minimal side effects due to their biosimilar structure.
Eosinophilic Esophagitis (EoE) and Dupilumab (Dupixent)
Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition that affects the esophagus, causing symptoms such as difficulty swallowing, food impaction, and heartburn. Over time, EoE can lead to damage and scarring of the esophagus. It is associated with an elevated number of eosinophils, a type of white blood cell, in the esophagus, which causes inflammation and tissue damage.
Dupixent (dupilumab) is a revolutionary biologic medication that was recently approved by the FDA to treat EoE in adults and children aged 1 year and older (weighing more than 33 lbs). Dupixent is the first treatment of its kind for EoE, offering new hope for patients by reducing inflammation and the number of eosinophils in the esophagus, thus managing symptoms and preventing long-term damage. Dupixent is administered as an injection, and its approval marks a significant advancement in the management of EoE.
Biologics in Allergy Treatment
Biologic medications have transformed the treatment landscape for several allergic and immune system conditions. Below are some of the biologics we offer at The Allergy Group, and the conditions they treat:
Fasenra (benralizumab)
- Indication: Allergic Asthma
- Administration: Injectable
- Fasenra is designed to reduce the number of eosinophils, which are involved in the inflammation of the airways in patients with allergic asthma. It helps prevent asthma attacks and improves overall lung function.
- Ages 6 years and older
Dupixent (dupilumab)
- Indications:
- Eosinophilic Esophagitis (EoE)
- Allergic Asthma
- Nasal Polyps
- Atopic Dermatitis (Eczema)
- Prurigo Nodularis
- Administration: Injectable
- Dupixent works by inhibiting certain proteins in the immune system that cause inflammation, providing relief for a range of conditions from skin disorders to respiratory issues.
- Ages 6 months and older(varies by condition being treated)
Xolair (omalizumab)
- Indications:
- Chronic Spontaneous Urticaria (Hives)
- Nasal Polyps
- Allergic Asthma
- Food Allergy
- Administration: Injectable
- Xolair targets immunoglobulin E (IgE), which plays a role in allergic reactions. It is used to manage severe asthma and other conditions where IgE contributes to symptoms.
- Ages 1 year and older(varies by condition being treated)
Nucala (mepolizumab)
- Indications:
- Allergic Asthma
- Nasal Polyps
- Hyper Eosinophilic Syndrome (HES)
- Eosinophilic Granulomatous Disease with Polyangiitis (EGPA)
- Administration: Injectable
- Nucala targets interleukin-5 (IL-5), a protein that promotes eosinophil production, helping to control diseases that involve high levels of eosinophils.
- Ages 6 years and older(varies by condition being treated)
Tezspire (tezepelumab-ekko)
- Indication: Severe Asthma
- Administration: Injectable
- Tezspire is a novel biologic for severe asthma that works by blocking a molecule called thymic stromal lymphopoietin (TSLP), which is involved in asthma inflammation. It is effective for a wide range of asthma types.
- Ages 12 years and older
Adbry (tralokinumab-ldrm)
- Indication: Atopic Dermatitis (Eczema)
- Administration: Injectable
- Adbry works by targeting interleukin-13 (IL-13), a key player in the inflammatory process of eczema, helping to reduce the severity of skin lesions and itching.
- Ages 12 years and older
Rinvoq (upadacitinib)
- Indication: Atopic Dermatitis (Eczema)
- Administration: Oral
- Rinvoq is a Janus kinase (JAK) inhibitor that helps reduce inflammation by targeting specific pathways in the immune system. It is taken as an oral medication for moderate to severe eczema.
- Ages 12 years and older
Cibinqo (abrocitinib)
- Indication: Atopic Dermatitis (Eczema)
- Administration: Oral
- Like Rinvoq, Cibinqo is a JAK inhibitor that reduces inflammation and itching in patients with moderate to severe eczema. It offers an oral treatment option for those who may prefer not to use injections.
- Ages 12 years and older